• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Nivolumab plus ipilimumab improved long-term survival in patients with advanced melanoma  

byJamie ParkandSze Wah Samuel Chan
December 13, 2021
in Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The 6.5-year progression-free survival for the nivolumab combination group, nivolumab group and in the ipilimumab group were 34%, 29% and 7%, respectively.

2. There were no new safety signals that were identified since the 5-year analysis.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with advanced melanoma have improved survival outcomes from  immune checkpoint inhibitors and BRAF- and MEK-targeted therapies. Previous phase II CheckMate 069 and phase III CheckMate 067 trials established nivolumab and ipilimumab as a standard care option for patients with metastatic melanoma. The 5-year follow-up overall survival (OS) rate from the phase III CheckMate 067 study was 52% for the nivolumab plus ipilimumab group, 44% for nivolumab and 26% for those receiving ipilimumab. To explore long-term outcomes beyond the 5 years follow-up period, this study aimed to evaluate the 6.5-year efficacy and safety outcomes from the CheckMate 067 study. Both efficacy primary end points (progression-free survival (PFS) and overall survival (OS)) were longer in the nivolumab combination compared to the monotherapy group at the 77 months minimum follow-up. The 6.5-year PFS rates for the nivolumab combination group, nivolumab monotherapy group and in the ipilimumab group were 34%, 29% and 7%, respectively. The median OS for the nivolumab combination group, nivolumab monotherapy group and in the ipilimumab group were 72.1 months, 36.9 months and 19.9 months respectively. There were no new safety signals reported since the last safety analysis cutoff. Overall, this study demonstrated that nivolumab plus ipilimumab or nivolumab alone shows promise in its long-term efficacy and safety profile to treat patients with advanced melanoma.

Click to read the study in The Journal of Clinical Oncology

Relevant Reading: Five-year survival with combined nivolumab and ipilimumab in advanced melanoma

In-Depth [randomized controlled trial]: Patients were eligible if they had previously untreated, unresectable or metastatic stage III or IV melanoma with known BRAF V600 mutation status. The primary endpoints were progression-free survival (PFS) and overall survival (OS) in the combination or the nivolumab group versus the ipilimumab group. In total, 1296 patients were enrolled in the study between July 2013 to March 2014 and 945 were randomly, equally assigned to each treatment group (314 to combination therapy, 316 to nivolumab, 315 to ipilimumab). The minimum follow-up period for the study was 77 months at the October 2020 data cutoff. The median follow-up for each group were the following: combination (57.5 months), nivolumab (36.0 months) and ipilimumab (18.6 months). The median investigator assessed PFS in the combination group was 11.5 months (95% confidence interval [CI]: 8.7-19.3), 6.9 months (95% CI: 5.1-10.2) in the nivolumab group and 2.9 months (95% CI: 2.8-3.2) in the ipilimumab group. The median OS for the combination group, nivolumab group and in the ipilimumab group were 72.1 months (95% CI: 38.2 to not reached), 36.9 months (95% CI: 28.2-58.7) and 19.9 months (95% CI: 16.8-24.6) respectively. 11 patients (3 in combination, 3 in nivolumab, 2 in ipilimumab therapy) died between the previous 5-year analysis and the current analysis and are considered to be unrelated to the treatment.

RELATED REPORTS

#VisualAbstract: Combination of spartalizumab plus dabrafenib and trametinib does not significantly improve survival in BRAFV600-mutated metastatic melanoma

#VisualAbstract: FOLFOX in combination with nivolumab and trastuzumab improves survival in metastatic ERBB2⁺ esophagogastric adenocarcinoma

Survival is similar for patients with autoimmune disease treated with immune checkpoint inhibitors compared to patients with no autoimmune disease

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced melanomaanti-PD-L1 resistant melanomaimmunotherapy
Previous Post

Poziotinib reduces tumour size in patients with previously treated HER2 mutation positive non-small-cell lung cancer

Next Post

Suicide prevention videos may help improve suicidal ideation and help seeking in adolescents

RelatedReports

#VisualAbstract: Combination of spartalizumab plus dabrafenib and trametinib does not significantly improve survival in BRAFV600-mutated metastatic melanoma
StudyGraphics

#VisualAbstract: Combination of spartalizumab plus dabrafenib and trametinib does not significantly improve survival in BRAFV600-mutated metastatic melanoma

July 27, 2022
#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage
StudyGraphics

#VisualAbstract: FOLFOX in combination with nivolumab and trastuzumab improves survival in metastatic ERBB2⁺ esophagogastric adenocarcinoma

July 20, 2022
Oncology

Survival is similar for patients with autoimmune disease treated with immune checkpoint inhibitors compared to patients with no autoimmune disease

July 18, 2022
#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma
StudyGraphics

#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma

July 12, 2022
Next Post
Parents often unaware of adolescents’ suicidal thoughts

Suicide prevention videos may help improve suicidal ideation and help seeking in adolescents

#VisualAbstract: Mohs micrographic surgery is more cost effective than wide local excision for T2a cutaneous squamous cell carcinomas

#VisualAbstract: Mohs micrographic surgery is more cost effective than wide local excision for T2a cutaneous squamous cell carcinomas

Resident involvement may not increase postoperative complications in neurosurgery

Pericardiotomy after cardiac surgery may reduce the incidence of postoperative atrial fibrillation

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Ciprofol comparable to propofol for general anesthesia induction for gynecological surgery
  • Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy
  • Type of compensation model influences gender pay gap in primary care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.